Design and characterization of the tumor vaccine MGN1601
The tumor vaccine MGN1601 was designed and developed for treatment of metastatic renal cell carcinoma (mRCC). MGN1601 consists of a combination of fourfold gene-modified cells with the toll-like receptor 9 agonist dSLIM, a powerful connector of innate and adaptive immunity.02/11/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 11, 2016 Category: Urology & Nephrology Source Type: news

Side Effects With Sorafenib More Pronounced in Thyroid CancerSide Effects With Sorafenib More Pronounced in Thyroid Cancer
The incidence of side effects from the oral multikinase inhibitor sorafenib appears to be considerably higher among patients with differentiated thyroid cancer than those with renal cell or hepatocellular carcinoma. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 8, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Removal of complex renal tumors performed safely by robotic surgery in selected patients
(Elsevier Health Sciences) Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, report surgeons in The Journal of Urology®. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2016 Category: Cancer & Oncology Source Type: news

Consensus statement from the International Radiosurgery Oncology Consortium for Kidney
(Future Science Group) Future Science Group today announced the publication of a new article in Future Oncology, presenting a consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 3, 2016 Category: Cancer & Oncology Source Type: news

Nutrient deprivation kills kidney cancer cells
(Duke University) Duke researchers have exploited the greedy metabolism of cancer cells to target kidney cell carcinomas, which kill more than 100,000 Americans each year. The team showed that the majority of renal cell cancers rewire their metabolism in a way that leaves them addicted to the nutrient cystine. By depriving the cancer cells of cystine, the researchers were able to trigger a form of cell death called necrosis in tumor cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 3, 2016 Category: Cancer & Oncology Source Type: news

Celldex Therapeutics Initiates Phase 1/2 Study in Renal Cell Carcinoma
"Varlilumab is an attractive candidate for combination immunotherapy across a variety of cancers due to its target's restricted expression and strong activity in a variety of tumor models, as well as positive data and a favorable safety profile from our Phase 1 study."02/01/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 1, 2016 Category: Urology & Nephrology Source Type: news

Cancer / Oncology Neurology / Neuroscience Melanoma / Skin Cancer Radiology / Nuclear Medicine Nivolumab combined with radiation therapy may be new treatment option
Nivolumab has been approved by the Food and Drug Administration to treat advanced non-small cell lung cancer, renal cell carcinoma, and melanoma; however, the impact of nivolumab on brain metastases is unclear.01/28/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 28, 2016 Category: Urology & Nephrology Source Type: news

New Mesothelioma Clinical Trial Hopes to Improve Chemotherapy
This study is part of a broad development program that includes a number of additional planned studies." TRACON Pharmaceuticals develops novel targeted cancer therapies. Its TRC105 antibody is directed at renal cell carcinoma and hepatocellular carcinoma. This clinical trial with TRC102 is one of five nationally involving methoxyamine, but one of more than 200 trials for mesothelioma. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - January 27, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

Supinoxin™ Oral Administration Produces Clinically Meaningful Tumor Inhibition
In a poster presentation entitled “The Anti-Cancer Effects of Supinoxin (RX-5902) in Renal Cell Cancer,” Rexahn scientists detailed the results of several preclinical studies showing the antiproliferative effects of Supinoxin in various human renal cancer cell lines and xenograft renal cancer models.01/13/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 13, 2016 Category: Urology & Nephrology Source Type: news

Supinoxin ™ Oral Administration Produces Clinically Meaningful Tumor Inhibition
In a poster presentation entitled “The Anti-Cancer Effects of Supinoxin (RX-5902) in Renal Cell Cancer,” Rexahn scientists detailed the results of several preclinical studies showing the antiproliferative effects of Supinoxin in various human renal cancer cell lines and xenograft renal cancer models. 01/13/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 13, 2016 Category: Urology & Nephrology Source Type: news

Eisai submits EMA application of in-house developed lenvatinib for renal cell carcinoma
The number of patients with renal cancer in Europe is estimated to be 115,000,1 and renal cell carcinoma comprises more than 90% of all malignancies of the kidney.2 For advanced or metastatic renal cell carcinoma that is difficult to treat with surgery, the standard treatment method is molecular targeted drug therapy, however with low 5-year survival rates, this remains a disease with significant unmet medical need.01/12/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 12, 2016 Category: Urology & Nephrology Source Type: news

Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes of second-line therapies in mRCC
Dr de Velasco talks to ecancertv at ASCO GU 2016 about analysing when VEGF-targeted therapy for metastatic renal cell carcinoma (mRCC) is discontinued.01/09/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 9, 2016 Category: Urology & Nephrology Source Type: news

FDA to Review Expanded Indication for Cabozantinib
Exelixis announced that it has completed the submission of its rolling New Drug Application (NDA) with the Food and Drug Administration (FDA) and requested Priority Review for cabozantinib (tablet formulation) as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.01/04/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 4, 2016 Category: Urology & Nephrology Source Type: news

Nonprofit initiates new fund to assist Medicare patients with kidney cancer
HealthWell fund will provide financial assistance to under-insured patients with renal cell carcinoma.01/01/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 4, 2016 Category: Urology & Nephrology Source Type: news

FDA approves nivolumab for mRCC
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.11/23/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 2, 2015 Category: Urology & Nephrology Source Type: news

FDA Approves Nivolumab
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.11/23/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 24, 2015 Category: Urology & Nephrology Source Type: news

FDA Approves Nivolumab for Renal Cell CarcinomaFDA Approves Nivolumab for Renal Cell Carcinoma
The immunotherapy is the first treatment to show a survival benefit as a second-line therapy in patients with advanced disease. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 23, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Opdivo to treat advanced form of kidney cancer
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 23, 2015 Category: American Health Source Type: news

Offer It: Third-Line Therapy Effective in Metastatic RCCOffer It: Third-Line Therapy Effective in Metastatic RCC
Third-line therapy is prevalent, has demonstrated activity in metastatic renal cell carcinoma (RCC), and should be offered to eligible patients. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 9, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Meat cooked at high temperatures increases cancer risk
Stephen FellerHOUSTON, Nov. 9 (UPI) -- Researchers linked increased consumption of meat cooked at high temperatures with an increased risk for renal cell carcinoma, or kidney cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 9, 2015 Category: Consumer Health News Source Type: news

Increased meat consumption, especially when cooked at high temperatures, linked to elevated kidney cancer risk
(University of Texas M. D. Anderson Cancer Center) Diets high in meat may lead to an increased risk of developing renal cell carcinoma (RCC) through intake of carcinogenic compounds created by certain cooking techniques, such as barbecuing and pan-frying. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2015 Category: Global & Universal Source Type: news

Increased meat consumption, especially when cooked at high temperatures, linked to elevated kidney cancer risk
Diets high in meat may lead to an increased risk of developing renal cell carcinoma (RCC) through intake of carcinogenic compounds created by certain cooking techniques, such as barbecuing and pan-frying. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 9, 2015 Category: Cancer & Oncology Source Type: news

'Exceptional' Patients With RCC Have Distinct Characteristics'Exceptional' Patients With RCC Have Distinct Characteristics
Patients with renal cell carcinoma who achieve a durable response to anti-PD-1 therapy have distinct pathologic, genomic, and RNA expression profiles. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 7, 2015 Category: Consumer Health News Tags: Nephrology News Source Type: news

Initiation Of Phase III First-Line Trial Of Avelumab
The clinical development program for avelumab now includes more than 1,400 patients who have been treated across more than 15 tumor types, including breast cancer, gastric/gastro-esophageal (GEJ) cancers, head and neck cancer, Merkel cell carcinoma, melanoma, NSCLC, ovarian cancer, renal cell carcinoma and urothelial (e.g., bladder) cancer.11/05/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 5, 2015 Category: Urology & Nephrology Source Type: news

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma
We aimed to investigate whether expression in the primary tumour of genes involved in the development of BM is associated with outcome in m-ccRCC patients treated with anti-VEGFR-TKIs.11/04/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 4, 2015 Category: Urology & Nephrology Source Type: news

Arkadia-ESRP2 axis suppresses tumor progression
Tumor-specific alternative splicing is implicated in the progression of cancer, including clear-cell renal cell carcinoma (ccRCC).11/03/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 3, 2015 Category: Urology & Nephrology Source Type: news

A CpG-methylation-based assay to predict survival
Clear cell renal cell carcinomas (ccRCCs) display divergent clinical behaviours. Molecular markers might improve risk stratification of ccRCC.10/31/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 1, 2015 Category: Urology & Nephrology Source Type: news

Ablation for Renal Cell Carcinoma Improves Outcomes, Reduces Costs
Research finds that ablative techniques have widened the range of treatment options available to patients with renal cell carcinoma.(PRWeb October 21, 2015)Read the full story at http://www.prweb.com/releases/2015/10/prweb13031319.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 21, 2015 Category: Pharmaceuticals Source Type: news

Nintedanib Shows Promise For Advanced Renal Cell Carcinoma
Post-hoc analysis suggested that nintedanib may have been particularly effective in patients with liver metastases at baseline, extending both PFS (8.4 vs 5.6 months) and OS (12.1 vs 8.2 months) compared with sunitinib.10/17/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 17, 2015 Category: Urology & Nephrology Source Type: news

Lenvatinib Phase II Results Show Significant Improvement in Progression-Free Survival When Used With Everolimus
Phase II results show lenvatinib, when used in combination with everolimus, demonstrates significantly improved progression-free survival (PFS) versus everolimus alone in people with metastatic renal cell carcinoma (mRCC) following prior VEGF-targeted therapy.10/16/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 16, 2015 Category: Urology & Nephrology Source Type: news

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
This is a Phase II study to evaluate the efficacy and safety of savolitinib monotherapy (600 mg once daily) in papillary renal cell carcinoma (“PRCC”) in the United States, Canada and Europe. PRCC represents about 14% of all new cases of kidney cancer.10/15/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 15, 2015 Category: Urology & Nephrology Source Type: news

Silencing Estrogen Receptor-β with siRNA in Cultured Cells
Estrogen receptors α and β (ERα and ERβ) are the two genomic estrogen receptors. ERβ was the second of these receptors to be discovered; its structure is similar to that of ERα but they are different in histological distribution. However, the functions of ERα versus ERβ are still unclear. The ability of small interfering RNAs (siRNAs) to silence gene expression has proven to be invaluable for studying gene function in cultured mammalian cells. This chapter describes the use of siRNA to inhibit the expression of ERβ in renal cell carcinoma (RCC) and to further the understandi...
Source: Springer protocols feed by Biochemistry - October 12, 2015 Category: Biochemistry Source Type: news

Silencing Estrogen Receptor- & beta; with siRNA in Cultured Cells
Estrogen receptors & alpha; and & beta; (ER & alpha; and ER & beta;) are the two genomic estrogen receptors. ER & beta; was the second of these receptors to be discovered; its structure is similar to that of ER & alpha; but they are different in histological distribution. However, the functions of ER & alpha; versus ER & beta; are still unclear. The ability of small interfering RNAs (siRNAs) to silence gene expression has proven to be invaluable for studying gene function in cultured mammalian cells. This chapter describes the use of siRNA to inhibit the expression of ER & beta; in renal...
Source: Springer protocols feed by Biochemistry - October 11, 2015 Category: Biochemistry Source Type: news

RCC trials don’t mirror real-world experience
Researchers have found that real-world metastatic renal cell cancer patients being treated with tyrosine kinase inhibitors are often sicker than subjects in clinical trials for these drugs, leading to questions about safety for use in the very patients who need the drugs in clinical practice.10/06/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 6, 2015 Category: Cancer & Oncology Source Type: news

RCC trials don ’t mirror real-world experience
Researchers have found that real-world metastatic renal cell cancer patients being treated with tyrosine kinase inhibitors are often sicker than subjects in clinical trials for these drugs, leading to questions about safety for use in the very patients who need the drugs in clinical practice. 10/06/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 6, 2015 Category: Urology & Nephrology Source Type: news

Screening test predicts poor treatment response in mRCC
Expression levels of a key protein involved in tumor cell survival appear to predict response to standard first-line therapy in patients with metastatic clear cell renal cell carcinoma...10/01/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 1, 2015 Category: Cancer & Oncology Source Type: news

New drug improves outcome in treatment resistant kidney cancer
A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 28, 2015 Category: Science Source Type: news

New drug improves outcome in treatment resistant kidney cancer
(Dana-Farber Cancer Institute) A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 28, 2015 Category: Global & Universal Source Type: news

New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model has been validated for patients (pts) with mRCC in the second line TT setting. This model does not consider time from 1st to 2nd line therapy, tumor shrinkage during 1st line and tumor burden before 2nd line. We sought to investigate these factors in addition to IMDC ones.09/26/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 27, 2015 Category: Cancer & Oncology Source Type: news

Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial
We present efficacy and safety in a subset of pts who were treated with nivolumab beyond RECIST-defined progression to investigate the potential benefits of this treatment approach.09/26/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 27, 2015 Category: Cancer & Oncology Source Type: news

Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-ta
Lenvatinib (LEN) – n oral inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT – in combination with everolimus (EVE) improved median progression-free survival (PFS; 14.6 mo) vs EVE (5.5 mo; hazard ratio [HR] 0.40; 95% confidence interval [CI] 0.24–0.68; P (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 27, 2015 Category: Cancer & Oncology Source Type: news

Bristol's Opdivo boosts kidney cancer survival
The successful outcome means Opdivo is the first so-called immune checkpoint inhibitor drug to show an improvement in overall survival in patients with renal cell carcinoma (RCC), a common type of kidney cancer.09/26/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 26, 2015 Category: Cancer & Oncology Source Type: news

First-Ever Survival Bump in Renal Cell Cancer (CME/CE)
(MedPage Today) -- Immune therapy may pave way to eventual cure (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 26, 2015 Category: Hematology Source Type: news

Cabozantinib in Kidney Cancer: Longest PFS YetCabozantinib in Kidney Cancer: Longest PFS Yet
Another presentation hailed as practice changing for renal cell carcinoma shows the longest progression-free survival yet in pretreated patients. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 25, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Finally, Drug Improves Survival in Pretreated Kidney CancerFinally, Drug Improves Survival in Pretreated Kidney Cancer
The first trial to show an improvement in survival in the second-line treatment of renal cell carcinoma has been hailed here as practice-changing. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 25, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Breakthrough study demonstrates survival advantage with immune checkpoint inhibitor for advanced kidney cancer patients
(University of Texas M. D. Anderson Cancer Center) For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma, a patient population for whom treatment options are currently limited. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2015 Category: Cancer & Oncology Source Type: news

Breakthrough study demonstrates survival advantage with immune checkpoint inhibitor for advanced kidney cancer patients
For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited. Researchers at The University of Texas MD Anderson Cancer Center demonstrated a median overall survival benefit of 25 months with nivolumab, a Food and Drug Administration (FDA)-approved immunotherapy agent, compared with 19.6 months for everolimus, a current standard of care for patients with metastatic kidney cancer. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 25, 2015 Category: Cancer & Oncology Source Type: news

Switching Therapies in Advanced Renal Cell Carcinoma
Following progression on first-line therapy, patients with renal cell carcinoma (RCC) often do not need to be hurried to second-line treatment, says David F. McDermott, MD. If there is existing disease that is not harming the patient, and the patient feels well, there is no reason to switch therapies, adds Eric Jonasch, MD.09/22/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 22, 2015 Category: Cancer & Oncology Source Type: news

What's Hot at ECC 2015? Immunotherapy and Rare CancersWhat's Hot at ECC 2015? Immunotherapy and Rare Cancers
New data showing long-term efficacy with immunotherapies and clinical benefit in renal cell carcinoma and neuroendocrine tumors will be presented. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

miR‐372 suppresses tumour proliferation
Up to now, the role of miR‐372 in renal cell carcinoma has remained unknown; in this study, we have aimed to reveal its functional importance in this tumour.09/08/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 8, 2015 Category: Cancer & Oncology Source Type: news